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Abbreviations 
ABC transporters: ATP-Binding Cassette transporters 
ADME: Absorption-Distribution-Metabolism-Excretion 
AM: acetoxy methylester 
BSA: bovine serum albumin 
ATP: adenosine triphosphate 
BCRP: ABCG2 
Caco-2: Human colonic adenocarcinoma cells 
CHO: Chinese Hamster Ovary cells 
DDI: drug-drug interactions 
DMEM: Dulbecco's modified Eagle medium 
DMSO: dimethyl sulfoxide 
F12: Ham's F12 medium 
FDA: Food and Drug Administration 
GF: GF120918, elacridar 
HBSS: Hanks' balanced salt solution 
HDM-PAPMA: hexadecane artificial membrane permeability assay 
HIV: human immunodeficiency virus 
HPLC: high performance liquid chromatography 
LLC-PK1: porcine kidney epithelial cells 
MDCK: Madin-Darby canine kidney cells 
MDR: multidrug resistance 
MDR1: ABCB1 (P-glycoprotein) 
MXR: ABCG2 
P-gp: ABCB1 (P-glycoprotein) 
R123: Rhodamine 123 
Sf9 cells: Spodoptera frugiperda ovarian cells 
1 Introduction 
1.1 The first observations of the field 
It has been long known that when tumor cells are treated with a specific 
chemotherapeutic agent resistance against the cytotoxin often develops. Surprisingly, the 
acquired resistance is not restricted to the cytotoxic agent used, but it is also extended to 
other, structurally unrelated cytotoxins. This phenomenon is called multidrug resistance. 
30 years ago, when researchers were looking for the mechanism underlying multidrug 
resistance they identified a 170 kDa transmembrane glycoprotein in colchicine selected 
CHO cells (Juliano and Ling, 1976). They found that cells expressing this protein on their 
surface exhibit altered drug permeability, and therefore named it P-glycoprotein (P-gp). 
Twelve years later the amplification and extensive transcription of a gene in multidrug 
resistant cell lines was described (Shen et al., 1986). The gene was named mdrl for 
multidrug resistance, and based on the structure of the gene and sequence homologies it 
was proposed that it was an ABC transporter (Chen et al., 1986). The same year it was 
shown that the mdrl gene codes for P-glycoprotein (Ueda et al., 1986). These first 
observations showed that an ABC transporter is capable of transporting pharmaceuticals 
(chemotherapeutic drugs) thereby protecting cells from their toxic effect. Advance on the 
field of P-gp and multidrug resistance research played a central role in ABC transporter 
research ever since. 
Several years later it was accidentally discovered, that the product of the mouse 
Mdrla gene (rodents have two Mdrl genes designated Mdrla and Mdrlb) plays a central 
role in protecting mice from the neurotoxic effect of the antiparasite ivermectin. 
Mdrla (-/-) mice were 100-fold more sensitive to orally administered ivermectin, due to 
significantly higher brain-to-plasma ratios of the antiparasite when compared to wild type 
mice. It was proposed that ivermectin is a substrate of Mdrla that is located in the apical 
membrane of brain endothelial capillary cells and limits the entrance of ivermectin into 
the central nervous system (Schinkel et al., 1994). This was the first report showing that 
an ABC transporter can protect whole compartments of the human body from the toxic 
effects of a xenobiotic. 
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The last 15-20 years extensive research in this area resulted in significant advance in 
our understanding of how different ABC transporters modulate the different 
pharmacokinetic parameters of xenobiotics. It turned out that multiple ABC transporters 
located at different pharmacological barriers are important determinants of the ADME 
(Absorption-Distribution-Metabolism-Excretion) properties of several drug molecules. 
This current work does not aim to give a full overview of the countless examples of such 
drug-ABC transporter interactions. Recent reviews covering the topic in detail are 
available (Sarkadi et al., 2006), (Glavinas et al., 2004). Two transporters stand out as 
pivotal in determining the ADME properties of drugs: ABCB1 (MDR1, P-gp) and 
ABCG2 (BCRP, MXR). The aim of this work was to set up and validate in vitro methods 
to detect the interaction of drug molecules with these two transporters. Therefore, this 
introduction is focused on the structure and function of ABC transporters with particular 
attention on the biochemical characteristics of ABCB1 and ABCG2. Also, the currently 
available in vitro methods are reviewed and the current position and acceptance of these 
assays in pharmaceutical industry is analyzed in detail. 
1.2 General overview of ABC transporters 
1.2.1 The structure and function of ABC transporters 
ABC proteins form one of the largest protein families known. The family is 
characterized by a conserved structure of ABC binding domains (containing the "ATP 
Binding Cassette" motif) and transmembrane domains. In mammals, the functional ABC 
protein contains two ATP binding domains and two transmembrane domains. The four 
domains can be present in one polypeptide chain ("full transporters") or might be set up 
by the homo- or heterodimerization of two polypeptides containing one of each domains 
("half transporters"). Each transmembrane domain forms 6 transmembrane alpha-helices 
spanning the membrane. The two transmembrane domains together probably form a pore-
like structure creating a channel across the membrane. The transmembrane domains are 
thought to exist in an "open" and "closed" conformation regulated by ATP binding and 
hydrolysis. The change in conformation might be responsible for the translocation of 
compounds across the cell membrane, might open and close ion channels or serve as 
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regulators for complex, multi-protein receptors. Based on homology searches using the 
conserved ABC motif 49 human ABC proteins have been identified in the human 
genome. Based on similarity in the gene structure, order of the domains, and sequence 
homology these proteins are grouped into 7 families designated with letters A-G. The 
members of each family are designated by a number following the letter. 
ABC transporters transport substrates across the cell membrane against their 
concentration gradient (active transport). The energy requirement for this process is 
derived from ATP hydrolysis. It is believed that ATP binding and hydrolysis generates a 
conformation change in the ATP binding domain. The close interaction between the ATP 
binding domains and the transmembrane domains creates the transmission of force to the 
transmembrane domains resulting in a conformation change in the transmembrane 
domains driving substrate translocation. Several members of the ABC protein family 
were shown to be active transporters (Sarkadi et al., 2006). This work focuses on two 
such ABC proteins: ABCB1 and ABCG2. 
1.3 ABCB1 and ABCG2 
1.3.1 ABCB1 
ABCB1 was the first ABC transporter discovered. It is a full transporter; a 
glycosylated protein expressed in the apical membrane of cells. It is localized at several 
pharmacological barriers including the intestinal brush-border membranes, the 
canalicular membrane or hepatocytes, the apical membrane of the endothelial cells of the 
blood-brain barrier and the placental brush-border membrane. ABCB1 has high transport 
capacity and broad substrate recognition. Different, chemically unrelated molecules (e.g. 
anticancer drugs, HIV-protease inhibitors, antibiotics, antidepressants, antiepileptics, and 
analgesics) were shown to be transported substrates of ABCB1. The fluorescent 
molecules calcein AM, rhodamine 123 (R123) and Hoechst 33342 were also shown to be 
transported by ABCB1. The structural basis for the promiscuous behavior of the 
transporter is still under investigation. Based on the physicochemical properties of 
substrates identified it was proposed that the model ABCB1 substrate is amphipatic, with 
a molecular mass of 300-2,000 Da (Sarkadi et al., 2006). 
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1.3.2 ABCG2 
In 1998 researchers were studying mitoxantrone selected MCF-7 cells (derived from 
a breast cancer patient) and identified a novel ABC transporter that conferred resistance 
against mitoxantrone, doxorubicin, and daunorubicin (Doyle et al., 1998). The protein 
was named BCRP (Breast Cancer Resistance Protein) or MXR (Mitoxantrone Resistance 
Protein). In the standard nomenclature it is designated ABCG2. Later, it turned out that 
the selected cell line used in these studies expressed a mutant form of ABCG2 carrying a 
glycine at position 482. The wild type protein (482R) was cloned from human placenta 
(Allikmets et al., 1998). 
The ABCG2 transporter is a half transporter. It was shown that it functions as a 
homodimer (Ozvegy et al., 2001) and it is localized to the plasma membrane of cells 
(Rocchi et al., 2000). It is expressed on the intestinal brush-border membranes, the 
canalicular membrane or hepatocytes, the apical membrane of the endothelial cells of the 
blood-brain barrier and in the placental brush-border membrane (Litman et al., 2001). 
Interestingly, ABCG2 was also shown to be expressed in the mammary gland of 
mammals and its expression is strongly induced during lactation (Jonker et al., 2005). 
Similarly to ABCB1, ABCG2 has wide substrate specificity. Several chemotherapeutic 
drugs (e.g. mitoxantrone, methotrexate, topotecan) are actively pumped out of cells 
expressing ABCG2 thereby rendering these cells resistant to these cytotoxic agents. This 
suggests that ABCG2 might be responsible for multidrug resistance unrelated to the 
expression of ABCB1 (Litman et al., 2001). Estrone-3-sulfate and other sulfate 
conjugates were also reported to be ABCG2 substrates and it was proposed that one of 
the physiological functions of ABCG2 is to clear sulfate conjugates that are formed in the 
cytoplasm during metabolism (Adachi et al., 2005). Interestingly, using knock-out mice it 
was shown that Abcg2 is responsible for protection against the toxic effects of 
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pheophorbide A, a phototoxic degradation product of chlorophyll (Jonker et al., 2002). 
1.4 In vitro ABC transporter assay systems in drug research and development 
The discovery of the importance of drug-ABC transporter interactions in the ADME 
properties of drugs generated a new need in pharmaceutical industry: scientists involved 
in drug development realized, that by examining the interactions of the transporters with 
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pharmacological and toxic agents, a prediction for the cellular and tissue distribution of 
these compounds can be achieved. As the transporter interactions appear to be crucial in 
the later phases of drug development, scientists in pharmaceutical industry require low-
cost, high-throughput methods that allow them to screen huge compound libraries (up to 
hundreds of thousands of molecules). This way they can select compounds with the most 
advantageous transporter interaction profile in the early phases of drug discovery (early 
ADME prediction) to avoid transporter-related problems in the later phases of drug 
development. Although knock-out mice, as well as mutant mice and rat strains, deficient 
in functional expression of some ABC transporter proteins, are available, only in vitro 
techniques meet the high-throughput requirements of early ADME studies. 
1.4.1 Screening methods 
The functional in vitro test systems mostly rely on the detection of the translocation 
of a substrate or the detection of the hydrolysis of ATP. The interaction of the test drug 
with the transporter can be determined indirectly, as it modulates the transport of a 
reporter substrate. Alternatively, the interaction can be detected by directly measuring the 
translocation of the test drug. The "direct" assay is more suitable for substrate screening, 
while assays utilizing a reporter substrate are more relevant in interaction studies, and in 
screens to identify inhibitors. 
The target protein can be included in the assays in two major forms: in whole cells 
expressing the transporter, or in purified membrane vesicles. For whole cell studies a 
plethora of selected or transfected cell lines are available. Two major drawbacks of using 
selected cell lines are usually noted: (i) transporter expression pattern changes with time, 
and (ii) the cell line overexpresses other transporters with overlapping substrate 
specificities. Clearly, transfected cells, if available, are the experimental system of 
choice, as they harbor a well-defined modification and a more stable expression. 
The function of the transporters can also be studied in membrane vesicles prepared 
from cells or tissues that overexpress the transporter. This is a widely used technique that 
can be used in different high-throughput assay formats. Utilization of inside-out vesicles 
carry major advantages, such as (i) the test compounds and ATP have direct access to the 
cytoplasmic domains of the transporter, and (ii) since the direction of the transport is 
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occurring from outside to inside, the transport can be assayed by measuring the amount 
of substrate trapped inside the vesicle compartment. Membrane preparations, purified 
from cells expressing the transporter, or reconstituted from purified protein and lipid 
components have been described. 
Although membrane vesicles can be made from practically any kind of cells that 
express the transporter (e.g. selected cell lines, transfected cell lines, tissues), the most 
frequently used membrane preparations utilize baculovirus-infected Sf9 insect cells 
(Sarkadi et al., 1992). The advantage of this expression system is the particularly high 
transporter protein expression level (around 5-10 % of the total membrane protein is the 
expressed transporter). In addition, the heterologously expressed transporter is the only 
mammalian protein in this system. This makes the insect membranes a powerful tool in 
membrane-based assays. Membrane preparations from other expression systems are 
usually not suitable for ATPase measurements, due to low signal-to-noise ratio, as a 
consequence of a low transporter expression. Some ABC-transporter overexpressing 
vesicular membrane preparations are by now commercially available. Membrane 
preparations reconstituted from purified transporters and lipids offer excellent signal-to-
noise ratio (Lu et al., 2001). However, preparation of these membranes is laborious, and 
these reagents are not available commercially. 
1.4.2 Whole cell based assays 
Efflux transporter-expressing cells actively pump substrates out or the cell, which 
results in a lower rate of substrate accumulation, lower intracellular concentration at 
steady state, or a faster rate of substrate elimination from cells loaded with the substrate. 
If the substrate is cytotoxic, cells overexpressing the transporter are less sensitive to the 
toxic effect than the parental ones, and inhibitors or competing non-cytotoxic substrates 
restore sensitivity. These types of screens are often used in search of substrates and 
reversing agents of transporters involved in multidrug resistance (Breuninger et al., 
1995). 
Radioactive substrates are also used to measure the transport across the cell 
membrane, as the accumulation or extrusion of the radioactive signal is different for the 
transporter overexpressing cell lines compared to parental ones (Reid et al., 2003). As 
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most test compounds are not available in a radioactively labeled form, the "indirect" set-
up is more frequently used. 
Transported substrates can also be labeled by fluorescent dyes. Furthermore, 
fluorescent molecules can be substrates of different transporters. As most test drugs are 
non-fluorescent, this assay is also usually performed in an "indirect" set-up, using a 
fluorescent reporter substrate, such as Rhodamine 123 (R123), which is a substrate of the 
ABCB1 transporter (Feller et al., 1995). When cells are incubated with R123, the dye 
accumulates at a slower rate in cells overexpressing ABCB1 than in the parental ones, or, 
alternatively, ABCB1-expressing cells loaded with R123 extrude the dye faster than 
parental ones. Inhibitors or competing substrates of the ABCB1 transporter modulate the 
rate of R123 accumulation/extrusion. The most commonly used application is the 
measurement of the efflux of R123. Multiple drawbacks of this assay have been reported: 
(i) the dye displays poor cellular retention, and it interacts with different intracellular 
compartments result in a spectral and intensity shift (143), (ii) the initial concentration is 
cell-type dependent and (iii) the concentration of R123 changes during the measurement. 
It has also been reported that after the initial loading, cells have to be incubated for 1-2 
(Lee et al., 1994), or even 3-10 hours in clinical samples (Chaudhary and Roninson, 
1991). This long time-frame and the extensive washing of the cells prior to the plate 
reader analysis, makes this assay inapplicable for high throughput screening. 
Calcein AM has been used as a more suitable alternative for R123 transport assay 
(Homolya et al., 1993), (figure l.B). Calcein AM is also a substrate for ABCB1, but it is 
nonfluorescent. Intracellularly calcein AM is hydrolyzed by endogenous esterases, 
yielding a fluorescent product, calcein. Therefore, accumulation of the fluorescent dye 
can be detected without the need for washing steps, making this assay suitable for a high 
throughput screen format. The presence of ABCB1 in the cell membrane strongly reduces 
calcein accumulation, and inhibitors of ABCB1 produce an increased rate of 
accumulation, up to the level measured in the absence of the transporter, calcein has 
favorable spectral properties, such as bright fluorescence, that is insensitive to pH or to 
Ca2+ as well as Mg2+ concentrations, and does not show spectral changes upon 
accumulation in intracellular compartments or upon binding to intracellular structures. 
Both calcein AM and free calcein are also transported by ABCC1, thus the calcein assay 
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is applicable for the quantitation of both ABCB1 and ABCC1 activities (Hollo et al., 
1996). A suitable kit (MDQ kit) already exists for the specific diagnostic detection of 
ABCB1 and ABCC1 activities in clinical tumor samples (Karaszi et al., 2001). 
Similar dye transport-based assays utilizing Hoechst 33342 or pheophorbide A have 
been worked out to measure the activity of ABCG2 (Kim et al., 2002), (Robey et al., 
2004). Hoechst 33342 is a non-fluorescent substrate of both ABCB1 and ABCG2, and 
the dye becomes fluorescent after entering the cell and binding to DNA, making a high-
throughput application of the assay feasible. Pheophorbide A is an ABCG2 specific 
substrate which becomes fluorescent after it is chemically modified inside the cells and 
can be used in a similar fashion as Hoechst 33342. 
In vivo, drugs have to cross pharmacological barriers in order to get absorbed 
(intestinal epithelial cells), distributed (blood-brain barrier endothelial cells) or excreted 
(hepatocytes, proximal tubule epithelial cells). This transcellular movement is modeled 
by the monolayer efflux assays, alternatively termed as vectorial transport assays (figure 
1 .D). There are several cell lines that can be grown on a permeable support in a way that 
the cells form a confluent monolayer with tight junctions. The cell lines used in these 
assays are polarized epithelial or endothelial cells, with tight junctions. Most commonly 
the human intestinal epithelial line Caco-2, and transfected versions of the canine kidney 
cell lines MDCKI, MDCKII, or the porcine kidney epithelial cells LLC-PK1 are used. 
Test drugs can be applied to either side of the cell layer and the rate of transport across 
the monolayer is measured from the apical to basolateral (A-B) or from the basolateral to 
apical (B-A) direction. If an active transport process modulates the movement of the test 
drug across the cell membranes, the compound is transported at different rates in the two 
directions. Modulators, specific for efflux transporters, erase the difference in transport 
rate, confirming the drug - transporter interaction. Recently, a variation of the monolayer 
efflux assay, referred as equilibrium transport assay, has been described (Gaillard et al., 
2000). In this set-up, the compounds are simultaneously placed at an equal concentration 
to both the apical and the basolateral side. The redistribution of the compounds is 
monitored over up to two days. 
Once again, transfected cell lines seem to be more suitable for the studies as the data 
can be corrected for the contribution of endogenous transporters (Adachi et al., 2001), 
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and these cells provide more stable expression of the ABC transporters. It is important to 
note that at least some of the endogenous ABC transporter promoters are stress-sensitive 
(Sukhai and Piquette-Miller, 2000). Therefore, it is likely that cell lines that express ABC 
transporters from endogenous promoters will be more susceptible to mechanical and 
environmental stress (changes in temperature, acidity, oxygen and fuel supply) that may 
occur during cell culturing. 
1.4.3 Membrane based assays 
Membranes prepared form ABC transporter overexpressing cells, or reconstituted 
from purified protein and lipids can be used to assay the interaction of test drugs with 
ABC transporters in three basic assay formats: the ATPase assay, the vesicular transport 
assay and the nucleotide trapping assay. 
The ATPase assay is one of the most widely used assays to search for compounds that 
interact with different ABC transporters (Sarkadi et al., 1992). The assay (figure l.A) 
requires relatively high levels of transporter protein expression, thus mostly membrane 
vesicles prepared from recombinant baculovirus infected insect cells (e.g. Sf9 cells) are 
used for this purpose. These membrane preparations show a vanadate-sensitive ABC 
transporter ATPase activity that is modulated by interacting compounds. The rate of ATP 
hydrolysis is determined by measuring the liberation of inorganic phosphate. In the 
presence of transported substrates the ATPase activity of the transporter increases 
(activation protocol). Inhibitors that act in a non-competitive fashion or some slowly 
transported compounds inhibit the ATPase activity of the stimulated transporter 
(inhibition protocol). The main advantage of the ATPase assay is in its simplicity and 
reproducibility. 
A more direct measurement of substrate translocation is possible by quantitation of 
the intravesicularly trapped substrates in the vesicular transport assay (figure l.C). 
Successful vesicular transport studies have been reported using membranes from different 
sources (insect cells, transformed and selected cell lines, artificial membrane vesicle - see 
(Bodo et al., 2003), (Lu et al., 2001)). A suitable membrane preparation contains 
adequate amount of inside-out orientation vesicles (the rest is usually open fragments), 
and substrates are actively transported into the vesicles. Rapid filtration, using glass fiber 
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filters or nitrocellulose membranes, is used to separate the vesicles from the incubation 
solution, and the test compound, trapped inside the vesicles, is retained on the filter. The 
quantity of the transported unlabelled molecules can be determined by high resolution, 
high sensitivity analytical methods. Alternatively, the compounds are radiolabeled or a 
fluorescent tag is attached, and the radioactivity or fluorescence retained on the filter is 
quantified. 
This assay can also be performed in an "indirect" set-up, where interacting test drugs 
modulate the transport rate of a labeled reporter compound. The "direct" assay clearly has 
an advantage, however, some "fast diffuser" compounds (e.g. verapamil) redistribute so 
fast that the translocation assays yield conflicting data (Litman et al., 2001). A high 
throughput format of the vesicular transport assay has recently been published (Tabas and 
Dantzig, 2002). 
1.4.4 Screening strategies 
It is generally accepted that none of the in vitro assay systems available is suitable for 
straightforward predictions for the in vivo situation. Some methods (e.g. ATPase or 
vesicular transport) provide simple, low-cost and high-throughput solutions, but do not 
model the actual physical setup of the pharmacological barriers of the human body. Other 
methods (e.g. monolayer assays) are expensive and time consuming, yet, their design is 
more relevant to the in vivo situation. Therefore, a successful attempt to identify and 
characterize the interaction of compounds with ABC transporters should include a 
combination of different in vitro assays performed in an optimized sequence. This 
sequence is termed 'screening strategy' in pharmaceutical industry. The optimal 
screening strategy depends on the overall aims of the study. For example, if we would 
like to identify transporter-interacting drugs in a large compounds library, indirect, 
fluorescence-based cellular assays and the ATPase assay can be used the screen the 
molecules. This gives a combination of direct and indirect assays; however, even these 
large-scale screening methods should be used in a complementary fashion, as false 
positive or false negative results could be obtained if only one of these methods is used. 
Hits can then be further characterized by more expensive, lower-throughput assays. Other 
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strategies for other situations can also be worked out using different combinations of in 
vitro transporter assays. 
A B 
Figure 1. The principle and typical output of the ATPase assay (A), the Calcein assay (B), the direct 
vesicular transport assay (C). The physical setup of the monolayer efflux assay (D). 
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1.5 The current position and acceptance of in vitro transporter assays for 
ABCB1 and ABCG2 in the pharmaceutical industry 
It is generally accepted that ABCB1 is an important determinant of the ADME 
properties of several pharmaceuticals. The numerous examples regarding mainly oral 
absorption and brain-to-plasma distribution of drugs made ABCB1 interaction screening 
a must in pharmaceutical industry. Presently, the "gold standard" method for this purpose 
- supported by current FDA regulations - is the Caco-2 monolayer assay. FDA suggests 
two types of assays: (1) A-B and B-A transport of the test compound, and (2) inhibition 
of the A-B/B-A transport of digoxin to detect ABCB1 mediated drug-drug interactions. 
Recent publications clearly pointed out, that this approach yields conflicting results (Polli 
et al., 2001), (Rautio et al., 2006). On one hand, several compounds that were shown to 
be substrates of ABCB1 by other methods (ATPase assay, cytotoxicity tests) do not 
appear to be transported substrates in the Caco-2 monolayer assay. On the other hand, 
some compounds that do not interact with ABCB 1 in other assays show up as transported 
substrates in this assay. Caco-2 cells express a wide range of different transporters and it 
was suggested that reason for the discrepancies might be related to other active transport 
processes. Inhibitors are often used to overcome the problem of multiple transporters 
involved in the process. GF120918 is widely used in ABCB1 research as a specific 
inhibitor, although this inhibitor was also shown to inhibit ABCG2 (Volk et al., 2002). 
An important advance on the field was the discovery of a high affinity, specific inhibitor 
of ABCB1 (LY335979, zosuquidar, (Slate et al., 1995)). The widespread use of this 
compound as an inhibitor might help in dissolving some of the contradictions caused by 
multiple transporters expressed in Caco-2 cells. Other researchers suggested using 
transfected cell lines (e.g. MDCKII-MDR1) for the monolayer studies. Yet, it was also 
shown that the parental MDCKII cells express a functional canine transporter with very 
similar biochemical characteristics to human ABCB1 (Taub et al., 2005). 
The Calcein assay and cytotoxicity tests are also widely used cell based assays. These 
methods are routinely used to screen for compounds that inhibit ABCB1. These 
compounds might cause ABCB1 mediated drug-drug interactions, but they can also be 
advantageous in overcoming ABCB1 mediated multidrug resistance (reversing agents). 
12 
Recent studies reported data suggesting that drugs that modulate the A-B/B-A transport 
of digoxin in Caco-2 cells also inhibit the calcein AM extrusion in the Calcein assay 
(Rautio et al., 2006) suggesting that the Calcein assay might be a suitable tool for the 
detection of compounds that cause ABCB1 mediated drug-drug interactions. This 
modification of the screening strategy would result in lower cost and higher throughput. 
The ABCB1 ATPase assay is a fairly widely used screening tool in pharmaceutical 
industry (e.g. Fantin et al., 2006). It is generally accepted that compounds that are 
transported at high turnover rates are readily detected in this assay. Yet, the acceptance of 
this assay as a general screening tool is hindered by two observations. (1) It is well 
known that several compounds that were shown to be transported by ABCB1 do not 
stimulate the vanadate sensitive ATPase activity of membrane preparations containing 
ABCB1. It has been hypothesized that these compounds are transported by ABCB1 with 
a low turnover rate that do not yield detectable amount of inorganic phosphate in the 
ATPase assay. (2) Several compounds that are not transported in the Caco-2 assay 
stimulate the ABCB1 ATPase activity. It was proposed, that the passive permeability of 
the test compounds might be responsible for the different outcomes in the different assays 
(Rautio et al., 2006). Theoretically, monolayer studies measure the sum of passive 
permeability and active transport. In case of highly permeable substrates the rate of the 
passive process might be significantly higher than the active transport, thereby making 
the transporter interactions undetectable in the monolayer assay. No studies reported so 
far aimed at dissecting the active and passive processes to test this theory. 
ABCB1 transports mainly hydrophobic substrates that easily cross the cell membrane; 
therefore, direct vesicular transport measurements for these substrates cannot be 
performed. There are some low permeability substrates (e.g. N-methyl-quinidine) for 
which successful vesicular transport experiments have been reported (Hooiveld et al., 
2002), however, these assays are not used in pharmaceutical industry. It is perceivable, 
that successful vesicular transport systems utilizing drugs that are known to interact with 
ABCB1 in vivo (e.g. digoxin) would be more popular than the currently available 
vesicular transport assays. 
In the recent couple of years the possible contribution of other transporters to the 
ADME properties of pharmaceuticals have been gaining wider acceptance. ABCG2 is 
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similar to ABCB1 in several respects: both proteins are expressed in several (and similar) 
pharmacological barriers, both transport a wide variety (and partially overlapping) 
substrates and both transporters are involved in the multidrug resistance phenomenon. 
Currently there are no FDA regulations regarding tests for the interaction of drugs with 
ABCG2, but the growing interest in the field indicates that ABCG2 might become an 
important transporter for pharmaceutical industry in the near future. Therefore, it is 
important to establish and validate high throughput functional assays that can be used to 
detect the interaction of test compounds with ABCG2. 
It has been shown that Caco-2 cells express functional ABCG2 on their apical 
membrane (Xia et al., 2005). While this might be the reason for the conflicting data for 
ABCB1 studies, it makes Caco-2 cells suitable for ABCG2 studies. Also, MDCKII cells 
transfected with mouse Abcg2 and human ABCG2 have been established and described 
in detail (Breedveld et al., 2004), (Pavek et al., 2005). The development of these assays 
has been greatly facilitated by the availability of a high affinity, specific inhibitor of 
ABCG2: Kol43 (Allen et al., 2002). Using these cell lines and specific inhibitors might 
allow the establishment of valuable tools, yet, similarly to ABCB1 monolayer studies 
passive permeability of the test compounds could be a limiting factor when using these 
assays. 
Fluorescent dye efflux assays (Hoechst 33342, pheophorbide A) are available to study 
the interaction of test compounds with ABCG2. These assays are mostly used to develop 
reversing agents against ABCG2 mediated multidrug resistance (Robey et al., 2004). This 
approach might also become interesting for pharmaceutical industry for identifying 
compounds causing ABCG2 mediated drug-drug interactions. 
The first ABCG2 ATPase assays utilizing Sf9 membranes were reported on the 
R482G version of the transporter (Ozvegy et al., 2001). This membrane preparation had 
very high baseline vanadate sensitive ATPase activity, which could be stimulated by a 
number of known ABCG2 substrates. Later studies showed that a single amino acid 
change resulted in significant changes in the substrate specificity of this protein; 
highlighting the importance of amino acid 482 in substrate binding and/or transport 
activity of ABCG2 (Ozvegy et al., 2002), (Ozvegy-Laczka et al., 2005). Sf9 membranes 
containing the wild type (482R) version of the transporter also exhibit high baseline 
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vanadate sensitive ATPase activity, which cannot be further stimulated by known 
ABCG2 substrates (Ozvegy et al., 2002), (Ozvegy-Laczka et al., 2004). It was proposed 
that the different glycosylation pattern and/or the different membrane composition of the 
Sf9 cells could be responsible for this phenomenon (Ozvegy et al., 2001). Altogether, no 
ATPase assay suitable for the identification of transported substrates of wild type 
ABCG2 has been established so far. 
The substrate specificity of ABCG2 partially overlaps with that of ABCB1 (Litman et 
al., 2000), yet, ABCG2 transports a number low permeability compounds like 
methotrexate and sulfate conjugates (Suzuki et al., 2003); (Imai et al., 2003). Vesicular 
transport assays utilizing 3H-methotrexate and 3H-estrone-3-sulfate have been established 
and are used in pharmaceutical industry to identify ABCG2 interacting compounds. 
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Aims of the work 
1. For ABCB1 the major goal was to compare different membrane based and cell 
based in vitro assays to show that current "gold standard" methods used in 
pharmaceutical industry (Caco-2 and MDCKII-MDR1 monolayer studies) can be 
replaced by the ABCB1 ATPase assay. We were interested in the reason for the 
discrepancies that have been described. We hypothesized that passive 
permeability has a significant impact on the outcome of the different cell-based in 
vitro assay systems and might be an important input parameter of a successful 
screening strategy. Our overall aim was to propose a general, high-throughput, 
cost-effective screening strategy suitable for the detection of compounds that 
interact with ABCB1. 
2. As no successful ABCG2 ATPase assay was reported suitable for the detection of 
transported substrates of the wild type (482R) ABCG2 transporter our primary 
goal was to set up such an ATPase assay. All reported ATPase assays were based 
on membranes prepared from the Sf9/baculovirus system, so we decided to 
change the expression system and prepared membranes from a selected human 
cell line overexpressing ABCG2. According to our hypothesis, the different 
glycosylation pattern and/or membrane composition might make these membrane 
preparations suitable for the detection of substrates of ABCG2 in the ATPase 
assay. 
3. Several high affinity inhibitors (e.g. Kol43) of ABCG2 have been reported. We 
hypothesized that suppressing the baseline vanadate sensitive ATPase activity of 
the ABCG2 membrane preparations by inhibitors might result in better signal-to-
background ratios and a more robust assay. 
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3 Materials and methods 
3.1 Chemicals 
Ritonavir and fluvastatin were obtained from Toronto Research Chemicals (North 
York, ON, Canada), topotecan was purchased from LKT Laboratories (St. Paul, MN, 
USA), doxorubicin was purchased from Alexis (Griinberg, Germany). Pantoprazole, 
pumafentrine, and tolafentrine were from ALTANA Pharma, Konstanz, Germany. 
GF120918 was synthesized at ALTANA Pharma, Konstanz, Germany. Kol43 and 
Kol34 was a kind gift of Dr. Gerrit-Jan Koomen, University of Amsterdam (Amsterdam, 
The Netherlands). [3H]cimetidine and [3H]methotrexate were acquired from Amersham 
Biosciences (Freiburg, Germany) or Moravek Biochemicals (Brea, CA, USA), calcein 
AM, [14C]caffeine, [14C]erythromycin and [3H]estrone-3-sulfate were purchased from 
Perkin Elmer/NEN (Boston, MA, USA). [3H]D-Mannitol was obtained from 
MP Biomedicals (Cambridge, UK), and [3H]mitoxantrone from Biotrend (Cologne, 
Germany). BXP-21 antibody was purchased from Abeam (Cambridge, UK). All other 
chemicals were purchased from Sigma. 
3.1.1 Training set 
A set of 40 drugs was selected based on the compound's passive permeability 
(Wohnsland and Faller, 2001) and their interaction with ABCB1. This set contained the 
following compounds: acyclovir, alprenolol, amiloride, antipyrine, atenolol, ceftriaxon, 
chloramphenicol, chloroquine, cimetidine, cyclosporine A, desipramine, digoxin, 
doxorubicin, erythromycin, fluvastatin, furosemid, guanabenz, imipramine, lansoprazole, 
levadopa, methotrexate, metoprolol, midazolam, mitoxantrone, naproxen, omeprazole, 
pantoprazole, prazosin, propranolol, pumafentrine, quinidine, ranitidine, ritonavir, 
sulfasalazine, sulpirid, terbutaline, testosterone, tolafentrine, topotecan and verapamil. 
3.1.2 Validation set 
Out of 1296 small molecules originating from different chemical series for which 
ABCBl-ATPase and passive permeability using HDM-PAMPA had been determined, 
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two subsets of compounds were selected. Subsets 1 and 2 contained compounds with 
molecular weights greater than 300 Da (to exclude paracellular transport) and mass 
balance between 0.8 and 1.2. All compounds stimulated basal ABCBl-ATPase activity. 
The compounds were discriminated according to their passive permeability with high 
permeable compounds (HDM-PAMPA Papp >50 * 10"6 cm/sec) grouped in Subset 1 and 
low permeable compounds (HDM-PAMPA Papp <5 * 10"6 cm/sec) in Subset 2. 
3.2 Passive permeability 
3.2.1 HDM-PAMPA assay 
Passive permeability was determined using hexadecane artificial membrane 
permeability assay (HDM-PAMPA) as described (Wohnsland and Faller, 2001). Assay 
plates were stirred on an orbital shaker at 100 rpm. Passive permeability was recorded 
after 5 or 96 h for compounds depending on high or low flux through the hexadecane 
layer. The sandwich was disassembled and the solutions in the acceptor and donor 
compartments were transferred to disposable UV-transparent plates (UV-Star®, Greiner-
BioOne, Frickenhausen, Germany). UV absorption was measured with a SAFIRE 
microplate spectrophotometer (Tecan, Mannedorf, Switzerland) scanning each compound 
from 240 to 450 nm, recording each compound at individual wavelengths yielding 
maximal UV absorption. Mass balance conditions were verified in order to assess 
retention of test compounds to the hexadecane layer or unspecific binding to assay plates. 
3.2.2 Estimation of passive permeability from molecular structure 
In case no experimental data was available for passive permeability (Kol43 and 
Kol34) we used the following equation (Guangli and Yiyu, 2006) to estimate Papp: 
logPapp = -0.18HBD + 0.095CPSA10 + 0.0026CPSA20 - 0.0051 TPS A - 4.42 
where HDB is the number of hydrogen-bond donors, CPSA10, CPSA20 and TPSA are 
descriptors of the polar surface area of the molecule. 
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3.3 Membrane preparation 
Transporter expressing Sf9 cells were obtained using recombinant baculoviruses. 
Recombinant baculoviruses encoding the wild type human ABCB1, ABCG2, inactive 
ABCG2-K86M mutant (carrying a mutation at a crucial position of the catalytic center of 
ATP binding and cleavage) or P-galactosidase were kindly provided by Prof. Sarkadi. 
The selected human cell line expressing wild type ABCG2 and the parental line were also 
kindly provided by Prof. Sarkadi. Human membrane vesicle preparations containing wild 
type ABCG2 (MXR-M) and control human membrane preparations (M-CTRL), as well 
as insect cell membranes containing the human ABCB1 (MDR1-Sf9) or ABCG2 (MXR-
Sf9) transporter and control insect membranes (beta-gal-Sf9-CTRL, MXR-K86M-Sf9-
CTRL) were prepared as described earlier (Sarkadi et al., 1992). Membrane protein 
contents were determined using a modified Lowry procedure (Bensadoun and Weinstein, 
1976). 
3.4 ABCG2 deglycosylation 
Enzymatic deglycosylation was performed using peptide-N-glycosidase F (PGNase F, 
Sigma-Aldrich). 1 pi of the enzyme (500 U/ml) was added to 50 pi of membrane 
suspension (5 mg/ml), mixed and incubated at 37 °C for 10 min. Deglycosylation was 
detected by Western blotting. 
3.5 Western blotting 
ABCG2 expression and apparent molecular weight was detected by SDS-PAGE and 
subsequent western blotting using specific anti-ABCG2 antibody BXP-21, HRP-
conjugated anti-mouse secondary antibody (Sigma) and enhanced chemiluminescence 
(ECL, Amersham Biosciences) as described earlier (Ozvegy et al., 2002). 
3.6 ATPase assay 
ATPase activity was measured as described earlier (Sarkadi et al., 1992). Briefly, 
membrane vesicles were incubated in 10 mM MgCl2, 40 mM MOPS-Tris (pH 7.0), 50 
mM KC1, 5 mM dithiothreitol, 0.1 mM EGTA, 4 mM sodium azide, 1 mM ouabain, 5 
mM ATP, and various concentrations of test drugs with or without 1.2 mM sodium 
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orthovanadate at 37 °C. ATPase activities were determined as the difference of inorganic 
phosphate liberation measured in the presence or absence of 1.2 mM sodium 
orthovanadate (vanadate sensitive ATPase activity). Results are presented as vanadate 
sensitive ATPase activités, or as relative activities (%), where 100% is the baseline 
vanadate sensitive ATPase activity of the membrane suspension. 
3.7 Vesicular transport assay 
Vesicular transport studies were performed as described (Bodo et al., 2003). Briefly, 
membrane fraction containing inside-out membrane vesicles were incubated in the 
presence or absence of 4 mM ATP in a buffer containing 7.5 mM MgCU, 40 mM MOPS-
Tris (pH 7.0), 70 mM KC1 at 37 °C in the presence of the indicated substrate and other 
compounds for the indicated times. The transport was stopped by addition of 1 ml of cold 
wash buffer (40 mM MOPS-Tris (pH 7.0), 70 mM KC1) to the membrane suspensions 
and then rapidly filtered through class F glass fiber filters (pore size, 0.7 pm). Filters were 
washed with 2x5 ml of ice cold wash buffer. When labeled compounds were used as 
substrates radioactivity retained on the filter was measured by liquid scintillation 
counting. For unlabeled compounds quantification was performed by HPLC. ATP-
dependent transport was calculated by subtracting the values obtained in the presence of 
AMP from those in the presence of ATP. 
3.8 Calcein assay 
K562-MDR cells, overexpressing ABCB1, were obtained from Dr. Sarkadi (National 
Medical Center, Institute of Hematology and Immunology, Budapest, Hungary). The 
cells were cultured as previously described (Homolya et al., 1996). After centrifugation at 
500 g, culture medium was removed and cells were resuspended in HBSS, pH 7.4, at 
lxlO6 cells/ml. 100 ¡Ltl of this suspension was added to each well of a 96well plate 
(Corning, Corning NY, USA). Test drugs and controls dissolved in DMSO were added at 
a volume of 2 pi and preincubated for 15 min at 37 °C. Calcein-AM dissolved in HBSS 
containing 50 pg/ml BSA was added to a final concentration of 250 nM to each well and 
fluorescence (excitation 485 nm, emission 538 nm) was recorded every 30 sec for 8 min. 
The slope of the fluorescence build-up for test drugs were plotted as relative inhibition 
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(%) based on fluorescence in the presence of 60 pM verapamil (positive control, 100%) 
and DMSO (blank control, 0%). The measurements were performed on a Fluoroskan 
Ascent microplate fluorometer (Thermo Electron Cooperation, Dreieich, Germany). 
3.9 Hoechst assay 
Selected human cells, overexpressing ABCG2, were obtained from Dr. Sarkadi 
(National Medical Center, Institute of Hematology and Immunology, Budapest, 
Hungary). The cells were cultured in DMEM:F12 1:1 mixture. After trypsinization and 
centrifugation at 500 g, culture medium was removed and cells were resuspended in 
HBSS, pH 7.4, at lxlO6 cells/ml. 100 pi of this suspension was added to each well of a 
96well plate (Corning, Corning NY, USA). Test drugs and controls dissolved in DMSO 
were added at a volume of 2 pi and preincubated for 15 min at 37 °C. Hoechst 33342 
dissolved in HBSS containing was added to a final concentration of 50 pM to each well 
and fluorescence (excitation 355 nm, emission 460 nm) was recorded every 30 sec for 15 
min. The slope of the fluorescence build-up for test drugs were plotted as relative 
inhibition (%), based on fluorescence detected in the presence of 1 pM Kol43 (positive 
control, 100%) and DMSO (blank control, 0%). The measurements were performed on a 
Fluoroskan Ascent microplate fluorometer (Thermo Electron Cooperation, Dreieich, 
Germany). 
3.10 Caco-2 assay 
Caco-2 cells (batch #2463691) were obtained from the American Type Culture 
Collection (ATCC, Manassas, Virginia, USA) at Passage 17. The cells were grown in 
culture medium consisting of DMEM (Biochrom, Berlin, Germany), supplemented with 
glutamine, 4.5 g/L glucose, heat-inactivated fetal calf serum (20% v/v), lOOU/ml 
penicillin, and 100 pg/ml streptomycin as described earlier (Yee, 1997). 
For transport studies, cells from passage 55 to 70 were used by seeding them on semi-
permeable filter inserts (24 wells inserts, 0.4 pm pore size, Greiner-BioOne, 
Frickenhausen, Germany) at 2x10 cells per cm . The cells on the inserts were then 
cultured for 21 to 25 days prior to use. For transport experiments, the culture medium 
was removed from the filter inserts, which were then washed with HBSS and placed to a 
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new 24-well plate (Greiner BioOne, Frickenhausen, Germany) that had been pretreated 
by incubating 24 h with culture medium. The transport buffer was HBSS buffer 
containing 20 mM HEPES and 20 mM glucose monohydrate. The pH of both the apical 
and basolateral compartments was 7.4. The transport was started by addition of 350 pi of 
10 pM or 100 pM compound dissolved in transport buffer to the apical compartment. 
Subsequently, a 50 pi sample was taken from the donor compartment at t = 0 min to 
determine the initial concentration of substrate (Co) and stored at < - 1 8 °C until further 
analysis. Then, 750 pi transport buffer was added to the 24-well plates, i.e. the basolateral 
compartment. The plates, containing the filter inserts, were then incubated in a 
humidified incubator at 37 °C for 120 min being stirred on an orbital shaker at 300 rpm. 
Samples from both compartments were collected and stored at < -18°C . Markers for 
paracellular and transcellular flux, i.e. FITC-dextran and propranolol, were assayed in 
parallel in each set of experiments. 
ABCB1 function, i.e. the effect of ABCB1 on the permeability of test compounds in 
the absorptive (apical to basolateral) direction, was assessed by calculating the ratio of 
apparent permeability coefficients in the presence and absence of the ABCB1 inhibitor 
GF120918, added to the apical and basolateral compartment at 1 pM. The ratio of 
digoxin permeabilities was determined for each batch of Caco-2 monolayers in the 
presence and absence of 1 pM GF120918 to ensure comparable ABCB1 expression. Only 
Caco-2 monolayers exhibiting digoxin permeability ratios > 2.5 were used for further 
experiments. Mass balance conditions were verified by additional sampling in the donor 
compartment in order to assess retention of test compounds to the cell monolayer or 
unspecific binding to assay plates. All experiments were carried out in triplicate. 
3.11 Sample analysis 
All compounds were determined using an Agilent HPLC System 1100 (Agilent, 
Waldbronn, Germany) equipped with a binary pump. Compounds in Set 1 were eluted 
using a Synergy Fusion 4.0 pm particle size, 75x4.6 mm reversed phase column 
(Phenomenex, Darmstadt, Germany) in combination with a RP18 security guard 
10x3.0 mm precolumn as stationary phase. The mobile phases were: (A) 10 mM 
ammonium acetate buffer, pH 3.0 or 6.0 and (B) acetonitrile. Gradient runs were 
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programmed as follows: at a flow rate of 1.5 ml/min 5% B for 1 min, increase to 90% B 
in 6 min, 90% B for 1 min then re-equilibration with 5% B for 2 min, until the next 
sample was injected. Compounds in Set 2 were eluted using a Synergy Fusion, 
Mercury MS 2.0 pm particle size, 20x4.0 mm reversed phase column (Phenomenex, 
Darmstadt, Germany) as stationary phase. The mobile phases were: (A) 10 mM 
potassium dihydrogenphosphate, pH 3.0 or 10 mM ammonium acetate buffer pH 6.0 and 
(B) acetonitrile. Gradient runs were programmed as follows: at a flow rate of 2.0 ml/min 
5% B, increase to 90% B in 3 min, 90% B, decreased to 5% B in 0.5 min followed by re-
equilibration with 5% B for 1 min until the next sample was injected. 
[14C] and [3H]-labeled compounds were determined by liquid scintillation counting on 
a Wallac Pharmacia S1414 scintillation counter (Perkin Elmer, Rodgau, Germany). 
3.12 Data analysis 
3.12.1 Apparent permeability (Papp) 
The apparent permeability coefficients (Papp) were calculated as follows: 
CR(t) V xV P =-1 l i s x ln 
(VD+VR)xAxeaxt CF Eq y 
where Vp is the volume of the donor compartment, VR is the volume of the acceptor 
compartment, A is the accessible filter area, t is the incubation time, CR(t) is the 
concentration in the receiver compartment at time point t, and C ^ is the concentration 
corresponding to a full equilibrium of the compound in the donor and acceptor 
compartment (Wohnsland and Faller, 2001). The Papp was corrected for the apparent 
porosity (ea) according to (Nielsen and Avdeef, 2004) using ea -HDM-PAMPA= 0.495 
and £a - Caco-2= 1.0. 
A retention factor (Rm) for all permeability experiments was calculated to assess mass 
balance conditions as follows: 
CD(t) + CR (t) 
M 
where Cp(t) and CR(t) are the concentrations in the donor and receiver compartment, 
respectively at time point t. 
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3.12.2 ABCB1 -ATPase kinetics 
Vmax and Km values for formation of inorganic phosphate from ABCBl-ATPase 
experiments were estimated by analysis of untransformed reaction velocity data via 
nonlinear regression. Compounds that stimulated ABCBl-ATPase activity without 
inhibition at higher concentrations were fitted to a modified form of the Michaelis-
Menten equation: 
( V ^ - V o J S VS=Vo 
CS + Km) 
where Vs is the ATPase activity as a function of the substrate concentration S, V0 is 
the basal activity (the activity in the absence of modulator). 
Drugs that stimulated ATPase activity at low concentrations but inhibited activity at 
higher concentrations were fitted using the following equation. 
KXK2V0 + K2VXS + V2S2 Vc = 
KXK2+K2S + S2 
where Vs is the ATPase activity as a function of the substrate concentration S, Vq is 
the basal activity (the activity in the absence of modulator). V/ is the maximal enzyme 
activity if only activation occurred and K/ is the substrate concentration that gives the 
half maximal increment in this ATPase activity. V2 is the activity at infinite concentration 
of the modulator, and K2 is the substrate concentration that gives half-maximal reduction 
of ATPase activity from the value V/. This equation is based on conventional enzyme 
kinetics algebra for a model that has an activity V/ with one substrate molecule (S) 
bound, and a, lower, activity 1 of magnitude V2 with two substrates (S) molecules bound 
(Litman et al., 1997). The data were analyzed by use of GraphPad Prism software 
(version 4.0 GraphPad, San Diego, USA). 
3.12.3 ABCB1 inhibition 
The inhibitory potency of compounds subjected to the Calcein assay was expressed as 
IC50 (concentration leading to half maximal inhibition). The ICso-values were calculated 
using the four-parameter equation with a variable slope. 
Bottom + (Top - Bottom) 
Inhibition = j_ |_]Q(( log/C 5 0 -S)xA) 
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where Bottom is the minimal and Top is the maximal inhibition observed and h refers 
to the Hill constant. 
3.12.4 Statistical analysis 
Assays were run in duplicates or triplicates and unbiased ("n-1") standard deviation 
was calculated and plotted. Cutoff values in screening were defined as: 
Cutoff = Baseline + 3Me, 
where Me is the median of the unbiased ("n-1") standard deviations of the duplicate 
or triplicate measurements of the dataset. 
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4 Results 
4.1 ABCB1 studies 
In order to measure passive permeability and transporter interactions independently 
from each other we chose two different assays. We used HDM-PAMPA to determine 
passive permeability, while we used the ATPase assay utilizing inside-out membrane 
vesicles and open membrane fragments to measure transporter interactions. We then 
assayed the compounds with the Calcein assay and the Caco-2 monolayer efflux assay 
using GF120918 as inhibitor of ABCB1. In these two methods we expected that both 
passive permeability and transporter interactions can modulate the outcome of the assay. 
Table 1 shows the assay systems used, assay conditions and determined parameters. 
Assay Test compound concentration(s) Determined parameters 
HDM-PAMPA 100 gM HDM-PAMPA Papp 
ATPase assay 
8 concentration points (3-fold 
dilution) starting at 100 or 300 
gM 
Stimulation (Y/N), KM or 
K1 (ATPase K) 
Calcein assay 
8 concentration points (3-fold 
dilution) starting at 100 or 300 
gM 
IC50 (Calcein IC50) 
Caco-2 (A-B) assay in the absence 
of GF120918 10 gM or 100 gM Papp Caco-2 (A-B) -GF 
Caco-2 (A-B) assay in the presence 
of 1 gM GF 120918 10 gM or 100 gM 
Papp Caco-2 (A-B) +GF 
Table 1. Assays used, test compound concentrations and determined parameters. 
We calculated the ratio of Calcein IC50 and ATPase K (Calcein IC50/ATPase K) and 
the ratio of A-B permeability for Caco-2 cells in the presence and absence of GF120918 
(Caco-2 Papp +GF/-GF). Using the determined and calculated values we tried to set up 
correlations to see if the other parameters are dependent on passive permeability (HDM-
PAMPA P a p p ) . Figure 2.A shows the correlation between HDM-PAMPA Papp, ATPase 
(Y/N) and Caco-2 Papp +GF/-GF for the training set. Compounds that did not stimulate 
the vanadate sensitive ATPase activity in the ATPase assay (open circles) did not show 
GF120918 sensitive A-B permeability in the Caco-2 assay (cutoff 1.5) regardless of 
HDM-PAMPA Papp values. Compounds that stimulated the vandate sensitive ATPase 
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activity in the ATPase assay (closed circles) with high permeability (HDM-PAMPA Papp 
> 50* 10"6 cm/s) exhibited no GF120918 dependent A-B permeability in the Caco-2 
assay, while compounds with low permeability (HDM-PAMPA Papp < 5*10"6 cm/s) 
exhibited GF120918 sensitive A-B permeability. Some compounds with medium 
permeability (5 *10"6 cm/s < HDM-PAMPA Papp < 50* 10"6 cm/s) showed GF120918 
dependent A-B permeability in the Caco-2 assay, while some did not. Figure 2.B shows 
the correlation between Papp PAMPA and Calcein IC50/ATPase K for compounds of the 
training set that exhibited stimulation in the ATPase assay. The ratio for the kinetic 
constants fell in the 0.3 - 3.9 range with average ratio of 1.43 and showed no correlation 
with passive permeability. 
We realized that the training set only contained four compounds that stimulated the 
vanadate sensitive ATPase activity in the ATPase assay, and showed low permeability 
(<5*10"6 cm/s) in the HDM-PAMPA assay. Therefore, we screened 1296 molecules 
using the ATPase assay and the HDM-PAMPA assay. We chose 23 compounds that 
showed stimulation in the ATPase assay: 11 compounds with low permeability (HDM-
PAMPA P a p p < 5*10"6 cm/s) and 12 with very high permeability (HDM-PAMPA Papp > 
50* 10"6 cm/s) (validation set). We next measured and calculated the same parameters as 
we did for the training set. Figure 2.C shows the correlation between HDM-PAMPA Papp 
and Caco-2 Papp +GF/-GF for the validation set. High permeability compounds did not 
exhibit GF120918 sensitive A-B permeability in the Caco-2 assay, while most low 
permeability compounds did (10 out of 11, cutoff 1.5). Figure 2.D shows the correlation 
between Papp PAMPA and Calcein IC5o/ATPase K for the validation set. For the high 
permeability subset of compounds the ratio of the kinetic constants fell in the 0.27 - 2.6 
range with average ratio of 1.47, while for the low permeability subset it fell in the 1.32 -
22.1 range with average ratio of 8.1. 
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Figure 2. (A) Correlation between HDM-PAMPA Papp, ATPase (Y/N) and Caco-2 Papp +GF/-GF. 
Filled and open circles: compounds that stimulated and compounds that did not stimulate the vanadate 
sensitive ATPase activity in the ATPase assay, respectively. Cutoff (1.5) is also shown. (B) Correlation 
between HDM-PAMPA Papp and Calcein IC50/ATPase K for compounds that stimulated the vanadate 
sensitive ATPase activity in the ATPase assay. (C) Correlation between HDM-PAMPA Papp and Caco-
2 Papp +GF/-GF for the validation set. Cutoff (1.5) is also shown. (D) Correlation between HDM-
PAMPA Papp and Calcein IC5o/ATPase K for the validation set. See text for further details. 
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4.2 ABCG2 studies 
4.2.1 Comparison of ABCG2 activity in human (MXR-M) and in SJ9 (MXR-Sf9) 
membranes 
To compare the ABCG2 content and glycosylation level of the membrane 
preparations we used western blotting using BXP-21, an ABCG2 specific antibody 
(figure 3.). Sf9 preparations containing the wild type or the defective (K86M) transporter 
(MXR-Sf9, lane 1 MXR-K86M-Sf9-CTRL, lane 2.) displayed a strong band with 
apparent molecular weight of 55-60 kDa. No band was detected in membrane 
preparations prepared from Sf9 cells infected with the baculovirus containing (3-
galactosidase gene (beta-gal-Sf9-CTRL, lane 3.). Membrane preparations from the 
selected human cell line exhibited a strong band with an apparent molecular weight of 70 
kDa (MXR-M, lane 4.) that was absent in membrane preparations obtained from the 
parental line (M-CTRL, lane 5.). 
To compare the MXR-M and the MXR-Sf9 membrane preparations we first 
determined the vanadate sensitive ATPase activity of the membrane preparations at 
different ATP concentrations, (figures 4.A-B). Both membrane preparations showed 
similar KM-values for ATP (2.0 and 2.2 mM for MXR-Sf9 and MXR-M membranes, 
respectively). ATP dependent [3H]-methotrexate vesicular transport measurements 
(figures 4.C-D) revealed that [3H]-methotrexate transport had similar KM-values (3.9 mM 
and 3.6 mM for MXR-Sf9 and MXR-M membranes, respectively). The transport of 3H-
methotrexate could not be observed in Sf9 membranes containing the K86M defective 
mutant version of ABCG2, nor in membranes prepared from the unselected, ABCG2 
non-overexpressing human cell lines (data not shown). 
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Figure 3. ABCG2 levels in the 
different membrane preparations as 
detected by the monoclonal antibody 
BXP-21 in western blot. 10 pg of 
total membrane protein/sample were 
separated by 10% SDS-PAGE and 
blotted on PVDF membranes. The 
presence of ABCG2 was detected by 
the monoclonal antibody BXP-21 
and anti-mouse-HRP secondary 
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Figure 4. Vanadate sensitive baseline ATPase activity of MXR-Sf9 (A) and MXR-M (B) preparations in 
the presence of different ATP concentrations. Membranes containing 20 pg of total protein were incubated 
at 37 °C for 40 min. Insert: Lineweaver-Burk plot. ATP dependent ['H]-methotrexate transport for MXR-
Sf9 (C) and MXR-M (D) membrane vesicles at different methotrexate concentrations. Incubation time was 
the first linear phase of transport: 12 minutes and 4 minutes for MXR-Sf9 membrane vesicles and MXR-M 
vesicles, respectively. Insert: Lineweaver-Burk plot. 
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4.2.1 ABCG2 ATPase activity in MXR-M and in MXR-S/9 membranes - effect of 
substrates and inhibitors 
ABCG2 substrates sulfasalazine, topotecan and prazosin (Litman et al., 2000) (van 
der Heijden et al., 2004) showed only a slight modulation of the baseline vanadate 
sensitive ATPase activity of MXR-Sf9 membranes. Sulfasalazine appeared to be a weak 
stimulator, while topotecan and prazosin were weak inhibitors of the baseline activity 
(figure 5.A). The ABCG2 in human cell membranes could be stimulated by all three 
compounds (figure 5.B). All four inhibitors tested (Kol43, Kol34, Hoechst 33342 and 
GF120918) inhibited the baseline vanadate sensitive ATPase activity of the MXR-Sf9 
preparation. Kol43, Kol34 and Hoechst 33342 inhibited the baseline vanadate sensitive 
ATPase activity of the MXR-M preparation. In contrast, GF120918 showed inhibition at 
lower concentrations, while it exhibited increasing ATPase activity above 1 fiM (figures 
5.C-D). The MXR-Sf9 membrane preparation shows - 1 0 nmol Pi/mg/min vanadate 
sensitive ATPase activity in the presence of 100 nM Kol43 or 200 nM Kol34. Sf9 
membranes expressing the defective (MXR-K86M-Sf9-CTRL) version of ABCG2 show 
similar baseline vanadate sensitive ATPase activity, which was not modulated by any of 
the substrates tested (figure 5.E). The MXR-M membrane preparation shows no vanadate 
sensitive ATPase activity in the presence of 100 nM Kol43 or 200 nM Kol34. Control 
membranes prepared from the unselected, ABCG2 non-overexpressing human cell line 
also did not have any vanadate sensitive ATPase activity and could not be stimulated by 
any of the substrates tested (figure 5.F). 
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Figure 5. Vanadate sensitive ATPase activity of MXR-Sf9 (A, C) and MXR-M (B, D), defMXR-K86M-
Sf9 (E) and M-CTRL (F) preparations in the presence of ABCG2 substrates and inhibitors at different 
concentrations. Membranes containing 20 pg of total protein were incubated at 37 °C for 40 min in the 
presence of different concentrations of test compounds. 
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4.2.2 Deglycosylation of ABCG2 
We were interested if the different glycosylation of proteins in insect cells and 
mammalian cells is responsible for the difference observed in the ATPase assay. To test 
this hypothesis we enzymatically deglycosylated (PGNase F treatment) ABCG2 in the 
mammalian membrane. We found that the apparent molecular weight of ABCG2 in 
PGNase F treated mammalian membrane preparation was reduced to the apparent 
molecular weight of ABCG2 in the Sf9 membrane preparation as detected by western 
blot (Figure 6.A). We compared the vanadate sensitive ATPase activity of the treated and 
untreated human membrane preparations in the presence of different concentrations of 
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Figure 6. (A) PGNase treatment of MXR-M membrane preparation as detected by the monoclonal 
antibody BXP-21 in western blot. 10 pg of total membrane protein/sample were separated by 10% SDS-
PAGE and blotted on PVDF membranes. The presence of ABCG2 was detected by the monoclonal 
antibody BXP-21 and anti-mouse-HRP secondary antibody visualized with ECL detection. (B) Vanadate 
sensitive ATPase activity in the presence of sulfasalazine for PGNase treated and untreated MXR-M 
membranes. Membranes containing 20 pg of total protein were incubated at 37 °C for 40 min in the 
presence of different concentrations of sulfasalazine. 
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4.2.3 Drug-stimulated ABCG2 ATPase activity in a low background system 
We have studied whether by suppressing the basal ATPase activity employing an 
ABCG2 inhibitor we can acquire a more sensitive system that allows the detection of 
substrate stimulated ATPase. Using different concentrations of sulfasalazine as activator 
we tested all four inhibitors at different concentrations on both membrane preparations. 
The inhibition of ABCG2 ATPase activity by Kol43 (figures 7.A-B) and Kol34 (figures 
7.C-D) could be reversed by using increased concentrations of sulfasalazine. The 
apparent E C 5 0 for the activating effect of sulfasalazine shifted to higher concentrations 
(for MXR-M membranes 1.5 pM and 9.6 pM in the presence of 0 and 80 nM Kol43, 
respectively) suggesting that these interactions are competitive. Due to this competitive 
interaction as the inhibitors were added at higher concentrations the activating effect of 
sulfasalazine became evident for the MXR-Sf9 membranes. The inhibition by GF120918 
was similar to Kol43 and Kol34, except that increasing concentrations of GF120918 
caused a smaller shift in the apparent E C 5 0 values than in the case of Kol43/Kol34 
(figures 7.G-H). Inhibition by Hoechst 33342 could not be reversed even by the highest 
concentration of sulfasalazine used (figures 7.E-F). Therefore, inhibition by 
Kol43/Kol34 and GF120918 appeared to be competitive, while inhibition by Hoechst 
33342 did not. 
The assay using ABCG2 in membranes derived from human cells, with or without 
inhibition with Kol34 or Kol43 showed the best results, so we ran the experiment using 
different concentrations of Kol34 and the other two reference activators. Increasing 
concentrations of Kol34 inhibited the baseline vanadate sensitive ATPase activity as 
earlier, however, when looking at the activating effect of these two compounds we did 
not see any shift in apparent E C 5 0 values suggesting that the interaction of these two 
compounds with Kol34 is not competitive (figure 8.) 
We screened a library of 30 compounds at 100 pM using both membrane preparations 
with and without 100 nM Kol43 (table 2.). No interaction was detected with MXR-Sf9, 
yet using Kol43 allowed the detection of the known ABCG2 substrates sulfasalazine, 
topotecan and prazosin. The MXR-M preparation also detected the 3 known substrates in 
the absence of inhibitors, while applying Kol43 increased the signal-to-background (fold 
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activation) values up-to more than 4-fold. No false positives were seen for these 30 













Acyclovir 0.9 1.0 1.1 1.1 
Alprenolol-HCl 0.9 1.0 1.1 0.6 
Amilorid 1.0 0.9 1.1 1.1 
Ant ipyr in 0.9 0.9 1.0 1.0 
Atenolol 1.0 1.0 1.0 1.2 
Cef t r iaxon 0.9 1.0 0.9 1.1 
Chloramphenicol 0.4 1.1 0.9 1.7 
Desipramin 1.0 0.9 0.6 0.2 
Digoxin 0.2 1.0 0.3 0.8 
Doxorubicin 0.8 1.1 1.1 0.1 
Ery thromycin 0.9 I.I 0.9 0.7 
Guanabenz 0.5 1.0 1.0 0.2 
Imipramine 0.9 0.9 0.6 0.0 
Lansoprazol 0.2 1.0 0.4 0.9 
Levadopa 0.9 1.0 1.0 0.4 
Metoprolol 1.0 1.0 1.0 0.6 
Naproxen 0.5 1.1 1.0 0.6 
Omeprazol 0.5 1.1 0.8 0.5 
Prazosin 0.7 1.4 1.5 5.0 
Propanolol 0.8 1.0 1.0 1.0 
Pumafen t r in 0.6 0.8 0.6 0.1 
Quinidin 0.4 0.9 0.8 0.3 
Ranit idine 1.0 1.0 1.2 0.8 
Ritonavir 0.1 0.9 0.0 0.1 
Sulfasalazine 1.0 2.4 2.0 7.2 
Sulpirid 0.9 1.0 1.0 0.6 
Terbuta l in 0.5 1.0 0.9 0.7 
Testosteron 0.7 1.1 0.4 0.0 
Topotecan 0.8 1.3 2.1 2.7 
Verapamil 0.4 1.0 0.7 0.2 
Table 2. Fold activation (signal-to-background) values measured for the different assays in the presence of 







Figure 7. Vanadate sensitive ATPase activity plotted as relative activity (%) of MXR-Sf9 and MXR-M 
preparations in the presence of different concentrations of sulfasalazine (x-axis) and inhibitors (legend. A-B 
Ko 143 (nM), C-D Kol34 (nM), E-F Hoechst 33342 (pM), G-H GF120918 (pM)). 
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Figure 8. Vanadate sensitive ATPase activity plotted as relative activity (%) of the MXR-M membrane 
preparation in the presence of different concentrations of prazosin (A) or topotecan (B) and Kol34 (legend, 
nM). Membranes containing 20 pg of total protein were incubated at 37 °C for 40 min. 
4.2.4 Estrone-3-sulfate ATPase and vesicular transport 
To compare the kinetic parameters of ATPase and vesicular transport we measured 
the vanadate sensitive ATPase activity and the vesicular transport of the ABCG2 
substrate estrone-3-sulfate at different estrone-3-sulfate and Ko 134 concentrations. In the 
ATPase assay estrone-3-sulfate stimulated the baseline ATPase activity with a KM value 
of 22 pM. It also showed a competitive interaction with Kol34 similar to that of 
sulfasalazine. In the vesicular transport assay estrone-3-sulfate was transported with a Km 




Figure 9. (A) Vanadate sensitive ATPase activity of MXR-M preparations in the presence of different 
concentrations of estrone-3-sulfate and Kol34 (nM, legend). Membranes containing 20 pg of total protein 
were incubated at 37 °C for 40 min. (B) Lineweaver-Burk plot of the estrone-3-sulfate stimulated vanadate 
sensitive ATPase activity (v-v(0)) of MXR-M preparations in the presence of different concentrations of 
Kol34 (nM. legend). v-v(0) was calculated by subtracting the vanadate sensitive ATPase activity in the 
presence of the respective Kol34 concentration from the vanadate sensitive ATPase activity determined in 
the presence of both estrone-3-sulfate Kol34. (C) ATP dependent [1H]-estrone-3-sulfate transport for 
MXR-M membrane vesicles at different estrone-3-sulfate concentrations in the presence of different 
concentrations of Kol34 (nM, legend). Incubation time was 1 minute. (D) Lineweaver-Burk plot of figure 
C. 
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4.2.5 Comparison of membrane-based ABCG2 assays and the Hoechst assay 
During our validation work we compared the results obtained using the different 
membrane based assays with a whole cell based ABCG2 assay (Hoechst assay). Some 
compounds that modulated the vanadate sensitive ATPase activity in the ATPase assay 
and/or were detected as transported substrates in the vesicular transport assay also 
inhibited Hoechst 33342 extrusion (prazosin, Kol43, Kol34), while others (topotecan, 
sulfasalazine, methotrexate, estron-3-sulfate) did not. We measured (HDM-PAMPA) or 
estimated the Papp value for these compounds and found that compounds that inhibited 
Hoechst 33342 extrusion were shown/estimated to have significantly higher apparent 
permeability than compounds that did not modulate Hoechst 33342 extrusion (table 3.). 
Compound Inhibition of Hoechst 33342 efflux (% of Kol43) 
p 
(10-* cm/s) 
Prazosin 104+/- 11.5 3.13 
Ko l 43 100+/-3.7 60.25" 
Kol 34 98 +/- 4.8 75.85" 
Topotecan 1.1 +/- 5.8 0.61 
Methotrexate 4.5 +/- 3.9 0.02 
Sulfasalazine -4.3 +/- 7.3 0.03 
Estrone-3-sulfate 1.7 +/- 6.3 0* 
Table 3. Inhibition of Hoechst 33342 efflux measured in the Hoechst assay and passive permeability 
measured in the HDM-PAMPA assay or estimated from molecular structure (#) for compounds that showed 




5.1 ABCB1 studies 
Using two independent sets of compounds with high diversity in molecular structure 
we determined the correlation between results of HDM-PAMPA permeability, the 
ATPase assay, the Calcein assay and the Caco-2 monolayer efflux assay (figure 2.). We 
found that highly permeable compounds that stimulate the vanadate sensitive ATPase 
activity in the ATPase assay do not show ABCB1 dependent transport in the monolayer 
efflux assay. Results of the training set are in accordance with data previously reported 
(Rautio et al., 2006), (Polli et al., 2001). This finding strongly suggests that for highly 
permeable molecules the rate of passive transport across the cell monolayer is 
significantly higher than the rate of active transport making the transporter interactions 
undetectable in the monolayer assay. These "false negatives" generated by the monolayer 
efflux assay can become crucial in drug development, as these compounds do interact 
with the transporter and might cause ABCB1 mediated drug-drug interactions in the later 
phases of drug development in vivo. This possibility is clearly demonstrated by 
examining the correlation between the ATPase assay and the Calcein assay (an in vitro 
DDI model). For highly permeable molecules the two assays correlate perfectly with no 
striking differences (less than 3-fold) in the apparent kinetic constants. 
Despite of the limited number of low permeability compounds included in the study 
we can still conclude that the correlation of the different assays show a strikingly 
different pattern when compared with highly permeable ones. Most low permeability 
compounds exhibited GF120918 sensitive transport in the Caco-2 monolayer efflux assay 
suggesting that the rate of active transport is an important determinant of the movement 
of these molecules across cell membranes. Also, most of the low permeability ABCB1 
interacting compounds exhibited significantly higher IC50 in the Calcein assay (up to 22-
fold) than apparent affinity in the ATPase assay suggesting the intracellular concentration 
of these compounds can be significantly different from concentrations applied to the test 
buffer. However, there were some compounds where no ABCB1 mediated efflux or 
significant shift in the apparent binding constant in the Calcein assay was detected. One 
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possible explanation is that there are other active transport processes (uptake of efflux) 
that modulate the outcome of the cellular assays. Further studies on low permeability 
compounds are necessary to gain further insight into processes that are responsible for 
these differences. 
Passive permeability (10~6 cm/s) 
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Figure 11. The proposed screening strategy to identify ABCB1 interacting 
compounds and to predict the likely in vivo consequence of the interaction based on 
the ATPase assay and HDM-PAMPA assay. 
Based on these findings we set up a general screening strategy to describe the 
interaction of test compounds with ABCB1 (figure 11.). We suggest using the ATPase 
assay to identify compounds that stimulate ABCB1 ATPase activity. We also suggest 
running the assay in the presence of a known substrate of ABCB1 (e.g. verapamil). This 
assay system identifies inhibitors and slowly transported compounds as inhibitors of the 
verapamil stimulated vanadate sensitive ATPase activity (von Richter et al., manuscript 
under revision). For compounds that showed interaction in the ATPase assay (activation 
or inhibition) we suggest determining their passive permeability using the HDM-PAMPA 
assay. In case of low permeability compounds it is important to determine whether the 
compound exhibits ABCB1 dependent transport in the monolayer assay (Caco-2 or 
MDCKII-MDR1). This would indicate if the interaction with ABCB1 would likely result 
in limited absorption and/or limited BBB penetration in vivo. For high permeability 
compounds our recommendation is to run the Calcein assay. This assay would indicate if 
the compound is likely to cause ABCB1 mediated drug-drug interactions. It is important 
to note that the ATPase assay, the HDM-PAMPA assay and the Calcein assay are low 
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cost, high-throughput methods, while monolayer assays are expensive and time-
consuming studies. Also, most ABCB1 interacting compounds show high passive 
permeability (e.g. we had to screen 1296 compounds to find 11 ABCB1 interacting 
compounds with low passive permeability). Therefore, this strategy is also the most cost-
effective approach to screen for ABCB1 interactions and to predict the likely in vivo 
consequence of such interactions. 
5.2 ABCG2 studies 
We performed a comparative analysis of wild type ABCG2 in membrane preparations 
derived from baculovirus transfected Sf9 cells and selected human cells (MXR-Sf9 and 
MXR-M, respectively). Both transporter preparations had similar affinity for ATP and for 
[^-methot rexate . The MXR-M preparations showed significantly higher vmax for [ H]-
methotrexate transport (figure 4.). One of the possible reasons for this difference is the 
difference in vesicular content of the two membrane preparations. Substrates and 
inhibitors of ABCG2 inhibited the ATP dependent [3H]methotrexate transport in both 
membrane preparations, while non-interacting drugs did not modulate it (Glavinas et al., 
2007). In contrast, in the ATPase assays the same set of compounds showed a strikingly 
different pattern. In case of MXR-Sf9 preparations the baseline vanadate sensitive 
ATPase activity could not be further stimulated by ABCG2 substrates, while stimulation 
was detected for all substrates tested for MXR-M preparations (figure 5.). The substrate 
specificity of the transporter in the MXR-M ATPase assay correlated well with the 
substrate specificity in the vesicular transport inhibition experiment, and is in good 
agreement with published data (Litman et al., 2000) (van der Heijden et al., 2004). We 
showed that it is unlikely that the different glycosylation pattern of insect and mammalian 
preparations is responsible for the different behavior of the Sf9 and mammalian 
membrane preparations (figure 6.). In a later study we also showed that the reason for this 
difference is the different membrane cholesterol content of the insect and mammalian 
membrane preparations (Pal et al., 2007). 
When the basal ABCG2-dependent ATPase activity was suppressed by 
Kol43/Kol34, all known substrates of ABCG2 stimulated the ATPase activity in both 
types of ABCG2 preparations (MXR-Sf9 and MXR-M). This shows that the reason for 
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the unresponsiveness of the MXR-Sf9 preparation without inhibitors is not caused by 
altered substrate specificity of the transporter, but is due to the high baseline ATPase 
activity that cannot be further stimulated by ABCG2 substrates. By using ABCG2 
inhibitors the MXR-Sf9 membrane preparation was suitable for substrate identification, 
and it increased the signal-to-background ratio of the MXR-M preparation (table 2.). Due 
to the competitive nature of the interaction for sulfasalazine and Kol43/Kol34 using 
higher inhibitor concentrations resulted in an increased apparent EC50 (figure 7.). 
Therefore, the concentration of the inhibitor has to be set as a compromise between 
reasonable shift in E C 5 0 and adequately low baseline activities. For Kol43 this falls in the 
50-100 nM range, while due to its somewhat lower affinity for ABCG2 it is in the 100-
200 nM range for Kol34. For prazosin and topotecan increasing Kol43/Kol34 
concentrations did not result in an increased apparent E C 5 0 suggesting that these 
interactions are not competitive (figure 8.). This suggests that Kol43/Kol34 binds to the 
same binding site as the hypothesized endogenous substrate, sulfasalazine and estrone-3 
sulfate, while prazosin and topotecan binds to a different one. Multiple substrate/inhibitor 
binding sites for ABCG2 have been suggested previously (Ozvegy-Laczka et al., 2005). 
Our results also indicate the presence of more than one substrate binding site for the 
ABCG2 transporter. 
Estrone-3-sulfate was one of the best stimulator of the ATPase assay indicating high 
transport rate for this compound. The transport could also be detected in the vesicular 
transport assay, which allowed us to compare the biochemical characteristics of ATPase 
stimulation and vesicular transport. The KM value for ATPase stimulation (22 pM) and 
KM for vesicular transport (7.8 pM) were comparable. Stimulation and transport could be 
inhibited by Kol34 in a similar, competitive fashion (figure 9.). These results show that 
for estrone-3-sulfate kinetic parameters determined in the ATPase assay are reflective of 
the kinetic parameters of the actual transport. Further studies are necessary to see if the 
correlation of kinetic parameters holds true for different ABCG2 substrates. 
We used the Hoechst assay to test compounds that showed interaction with ABCG2 
in membrane-based assays and we found very poor correlation. This situation is similar to 
correlation studies conducted on membrane-based and cell-based ABCB1 assays. 
Therefore, we checked if the passive permeability of the test compounds can be 
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responsible for the poor correlation (table 3.). Our limited data (one cell-based assay, 
limited number of compounds, single concentration point) suggest that similarly to 
ABCB1 passive permeability of the compound tested is an important determinant in the 
outcome of cell-based ABCG2 assays. Fortunately, low permeability substrates of 
ABCG2 are not as uncommon as low permeability substrates of ABCB1. Therefore, it 
looks easier to design studies to set up correlations between membrane-based and cell-
based ABCG2 assays with regard to passive permeability than it was for ABCB1. 
6 Summary 
We designed and preformed a detailed study on the effect of passive permeability on 
the outcome of different in vitro assays used to detect compounds that interact with 
ABCB1. We found that passive permeability is a crucial parameter in choosing the right 
in vitro tool to detect ABCB1 interacting compounds. We set up a screening strategy 
based on the passive permeability of test compounds as detected by HDM-PAMPA 
which looks to be a cost-effective approach to screen for ABCB1 interactions. The 
screening strategy was also designed to avoid "false negatives" that might lead to 
significant consequences in the later phases of drug development. 
We successfully established an ABCG2 ATPase assay to identify substrates of the 
transporter. We showed that the human membrane preparation containing ABCG2 can 
distinguish between substrates and non-substrates. Suppressing the baseline vanadate 
sensitive ATPase activity by ABCG2 inhibitors Kol43 (50-100 nM) or Kol34 (100-200 
nM) allowed us to increase the signal-to-background ratio of the assay. In essence, using 
the human membrane preparation containing ABCG2 with Kol34 or Kol43 is a reliable, 
sensitive and robust assay that could be the preferred choice in screening for substrates of 
ABCG2. Hits of this high-throughput, inexpensive method can be further characterized in 
lower throughput, and significantly more expensive direct transport experiments using 
vesicular transport or monolayer studies. This way, the improved ATPase assay can be a 
valuable tool in drug development as part of a screening strategy. 
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